GleamWall
中文EN

SNGX SOLIGENIX, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 812796 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-85.8%
TTM net income YoY-34.6%
TTM EPS YoY60.7%
Revenue 3-yr CAGR-47.5%
Net income 3-yr CAGR—

Margins

Gross margin0.0%
Operating margin-7,907.7%
Net margin-6,925.1%
FCF margin—
EBITDA margin—

Returns

ROE-249.0%
ROA-88.1%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets54.1%
Debt / equity0.00x
Current ratio1.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$0
Cost of revenue———————$0
Gross profit———————$0
R&D expense$357,012$974,091$1.78M$2.28M$1.58M$1.68M$1.94M$2.66M
SG&A expense$1.02M$1.13M$1.10M$1.19M$996,604$1.09M$1.08M$1.05M
Operating income-$1.38M-$2.10M-$2.88M-$3.47M-$2.58M-$2.76M-$3.03M-$3.71M
Pretax income-$1.12M-$1.99M-$2.82M-$3.40M-$2.53M-$2.70M-$2.95M-$3.40M
Net income-$1.12M-$1.99M-$2.82M-$2.90M-$2.53M-$2.70M-$2.95M-$2.99M
EPS (basic)-0.05-0.12-0.28—-0.58-0.82-0.97—
EPS (diluted)-0.05-0.12-0.28—-0.58-0.82-0.97—
Weighted avg. shares (diluted)22.15M15.95M10.16M—4.33M3.28M3.05M—
Balance sheet
Cash & equivalents$9.02M$9.81M$6.03M$7.94M$10.53M$5.10M$7.30M$7.82M
Current assets$9.17M$10.17M$6.57M$8.85M$10.88M$5.32M$7.64M$8.83M
PP&E, net$5,480$6,577$7,675$8,772$7,812$8,114$5,505$6,113
Total assets$9.46M$10.50M$6.92M$9.24M$9.24M$5.76M$7.75M$8.97M
Current liabilities$3.06M$3.67M$3.62M$3.70M$3.42M$3.63M—$4.85M
Long-term debt———————$0
Total debt———————$0
Total liabilities$3.21M$3.85M$3.83M$3.94M$3.70M$3.93M$3.85M$4.85M
Shareholders' equity$6.26M$6.65M$3.09M$5.29M$7.60M$1.83M$3.90M$4.12M
Net debt———————-$7.82M
Shares outstanding23.37M21.64M10.52M10.09M9.86M3.50M3.18M2.51M
Cash flow statement
Operating cash flow-$1.42M-$1.71M-$2.36M-$2.75M-$2.93M-$2.74M-$1.85M-$2.23M
Capital expenditure———$1,962$608———
Free cash flow———-$2.75M-$2.93M———
Investing cash flow———-$1,962-$608———
Financing cash flow$636,378$5.49M$451,000$157,884$8.36M$545,635$1.32M$242,878
Stock-based compensation$86,634$115,972$121,208$320,125$104,346$99,513$63,599$155,547

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.